Search Results
MC# 16-07
An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
MC# 14-08
A Multicenter, Phase I/Ib, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects with Advanced Solid Tumors
MC# 16-09
A Phase I Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors
MC# 16-16
A Phase I/Ib Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
MC# 17-12
A Phase I/Ib First-In-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination with Cemiplimab in Adult Patients with Advanced Solid Tumors
MC# 17-23
A Dose-Finding Phase I Study Of Tas-120 In Patients With Advanced Solid Tumors With Or Without Fibroblast Growth Factor/Receptor (Fgf/Fgfr)-Related Abnormalities Followed By A Phase 2 Study In Patients With Advanced Solid Tumors With Fgf/Fgfr-Related Abnormalities
MC# 17-33
A Sequential 2-arm, Open-label Phase I Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors
MC# 18-14
An Open-label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies
MC# 18-15
A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies
MC# 16-39
Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas
MC# 17-04
Phase I/II Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNb-NIS), Monotherapy and in Combination With Avelumab in Patients with Refractory Solid Tumors
MC# 17-24
A Phase I Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas
MC# 17-39
A Phase I, Open-Label Study of GSK1795091 Administered in Combination with Immunotherapies in Participants with Advanced Solid Tumors
MC# 18-06
A Phase Ib/II, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of AZD9150 plus Durvalumab alone or in Combination with Chemotherapy in Patients with Advanced, Solid Tumors and Subsequently in Patients with Non-Small-Cell Lung Cancer
MC# 18-08
A Phase I/Ib Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
